Study of 3 Million Women: NSAIDs and Contraceptive Clot Risks

Venous thromboembolism rates among women using hormonal contraceptives rose sharply immediately around the time they started taking prescription non-steroidal anti-inflammatory drugs, according to a large European study published in 2026. The findings, reported by The Lancet Obstetrics, Gynaecology & Women’s Health, suggest that blood clot associations linked to the combined use of these medications may partly reflect the underlying health conditions that prompted the painkiller treatment rather than a direct pharmacological action alone.

Self-Controlled Case Series Across Four Countries

The study utilized a self-controlled case series design to examine medical records covering more than 3 million women aged 15 to 49 using hormonal contraceptives. Instead of comparing separate groups of medicine users, researchers analyzed periods within individual women who experienced venous thromboembolism, which encompasses deep vein thrombosis and pulmonary embolism.

The analysis evaluated prescription non-steroidal anti-inflammatory drugs alongside contraceptives categorized by their baseline clot risk. Among Danish users of high-risk contraceptives, the incidence rate ratio stood at 3.70 before exposure and surged to 12.29 during the first week of NSAID treatment, when compared with contraceptive use alone.

Paracetamol Control Reveals Underlying Illness Patterns

To test whether these spikes stemmed directly from the drugs or the conditions requiring them, investigators included prescribed paracetamol as a negative control. The paracetamol analysis revealed a similar pattern.

This parallel trajectory supports the possibility that the underlying illness or specific symptoms leading patients to seek pain relief contributed significantly to the observed associations. The study authors noted that they could not completely exclude a direct pharmacological effect from NSAIDs, but the temporal sequence complicates simple causal interpretations.

Clinical Implications for Safety Signals

The timing of prescriptions holds substantial weight when interpreting observational safety signals in clinical practice. When an association is already detectable before a prescription begins, attributing the entire subsequent increase in risk solely to that medication risks overlooking other medical explanations.

Painkiller prescriptions often coincide with an evolving health problem or acute inflammatory state. At the same time, the study authors emphasize that these results do not establish that every combination of analgesics and hormonal contraceptives is safe for every patient.

Evaluating Absolute Risk Versus Relative Estimates

Relative incidence estimates generated by large population studies do not describe an individual woman’s absolute likelihood of experiencing a blood clot. A large underlying population dataset does not automatically guarantee precise statistical estimates for every specific exposure subgroup.

Clinical decisions regarding analgesia and contraception require careful evaluation of individual patient circumstances and the primary indication for treatment, moving beyond reliance on single headline risk estimates. Additional research distinguishing precise prescribing indications, symptoms preceding diagnosis, and exact medicine exposure timing remains necessary to clarify whether an independent drug-related effect persists.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.